WallStreetZenWallStreetZen

NASDAQ: TVTX
Travere Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for TVTX

Based on 9 analysts offering 12 month price targets for Travere Therapeutics Inc

Min Forecast
$25.00-22.7%
Avg Forecast
$34.11+5.48%
Max Forecast
$47.00+45.33%

Should I buy or sell TVTX stock?

Based on 9 analysts offering ratings for Travere Therapeutics Inc.

Buy
Strong Buy
3 analysts 33.33%
Buy
4 analysts 44.44%
Hold
2 analysts 22.22%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model "Strong Buy" agrees with analyst consensus with a "Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their TVTX stock forecasts and price targets.

TVTX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-11-04
lockedlocked$00.00+00.00%2025-10-31
lockedlocked$00.00+00.00%2025-09-19
lockedlocked$00.00+00.00%2025-09-12
lockedlocked$00.00+00.00%2025-09-11Find Out Why
ScotiaBank
Top 6%
95
BuyMaintains$31.00-4.14%2025-08-07
Wedbush
Top 8%
93
BuyMaintains$32.00-1.05%2025-08-07
Citigroup
Top 29%
72
Strong BuyMaintains$32.00-1.05%2025-06-11
HC Wainwright & Co.
Top 2%
99
BuyAssumes$30.00-7.24%2025-06-11

1 of 1

Forecast return on equity

Is TVTX forecast to generate an efficient return?

Company
499.95%
Industry
285.59%
Market
231.17%
TVTX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is TVTX forecast to generate an efficient return on assets?

Company
68.29%
Industry
96.56%
TVTX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

TVTX earnings per share forecast

What is TVTX's earnings per share in the next 3 years based on estimates from 17 analysts?

Avg 1 year Forecast
-$0.93
Avg 2 year Forecast
-$0.13
Avg 3 year Forecast
$2.18

TVTX revenue forecast

What is TVTX's revenue in the next 3 years based on estimates from 16 analysts?

Avg 1 year Forecast
$486.6M+11.65%
Avg 2 year Forecast
$682.4M+56.57%
Avg 3 year Forecast
$891.8M+104.63%
TVTX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

TVTX revenue growth forecast

How is TVTX forecast to perform vs Biotechnology companies and vs the US market?

Company
26.96%
Industry
109.05%
Market
25.77%
TVTX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
TVTX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

TVTX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
TVTX$32.34$34.11+5.48%Buy
TARS$68.25$87.50+28.21%Strong Buy
KNSA$38.37$51.33+33.78%Strong Buy
IRON$83.85$113.78+35.69%Strong Buy
RARE$30.63$76.10+148.45%Strong Buy
View Top Biotech Stocks

Travere Therapeutics Stock Forecast FAQ

Is Travere Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 9 Wall Street analysts covering (NASDAQ: TVTX) stock is to Buy TVTX stock.

Out of 9 analysts, 3 (33.33%) are recommending TVTX as a Strong Buy, 4 (44.44%) are recommending TVTX as a Buy, 2 (22.22%) are recommending TVTX as a Hold, 0 (0%) are recommending TVTX as a Sell, and 0 (0%) are recommending TVTX as a Strong Sell.

If you're new to stock investing, here's how to buy Travere Therapeutics stock.

What is TVTX's earnings growth forecast for 2025-2027?

(NASDAQ: TVTX) Travere Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 47.92%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.93%.

Travere Therapeutics's earnings in 2025 is -$88,539,000.On average, 17 Wall Street analysts forecast TVTX's earnings for 2025 to be -$83,459,787, with the lowest TVTX earnings forecast at -$135,031,636, and the highest TVTX earnings forecast at -$48,851,891. On average, 17 Wall Street analysts forecast TVTX's earnings for 2026 to be -$11,658,244, with the lowest TVTX earnings forecast at -$701,463,044, and the highest TVTX earnings forecast at $253,654,047.

In 2027, TVTX is forecast to generate $194,995,989 in earnings, with the lowest earnings forecast at $65,762,160 and the highest earnings forecast at $562,736,201.

What is TVTX's revenue growth forecast for 2025-2027?

(NASDAQ: TVTX) Travere Therapeutics's forecast annual revenue growth rate of 26.96% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 109.05%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.77%.

Travere Therapeutics's revenue in 2025 is $435,827,000.On average, 16 Wall Street analysts forecast TVTX's revenue for 2025 to be $43,537,234,318, with the lowest TVTX revenue forecast at $34,824,419,115, and the highest TVTX revenue forecast at $51,200,539,126. On average, 16 Wall Street analysts forecast TVTX's revenue for 2026 to be $61,054,126,498, with the lowest TVTX revenue forecast at $41,108,060,640, and the highest TVTX revenue forecast at $79,854,051,848.

In 2027, TVTX is forecast to generate $79,795,000,112 in revenue, with the lowest revenue forecast at $59,071,419,732 and the highest revenue forecast at $107,098,375,419.

What is TVTX's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: TVTX) forecast ROA is 68.29%, which is lower than the forecast US Biotechnology industry average of 96.56%.

What is TVTX's Price Target?

According to 9 Wall Street analysts that have issued a 1 year TVTX price target, the average TVTX price target is $34.11, with the highest TVTX stock price forecast at $47.00 and the lowest TVTX stock price forecast at $25.00.

On average, Wall Street analysts predict that Travere Therapeutics's share price could reach $34.11 by Nov 4, 2026. The average Travere Therapeutics stock price prediction forecasts a potential upside of 5.48% from the current TVTX share price of $32.34.

What is TVTX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: TVTX) Travere Therapeutics's current Earnings Per Share (EPS) is -$1.03. On average, analysts forecast that TVTX's EPS will be -$0.93 for 2025, with the lowest EPS forecast at -$1.51, and the highest EPS forecast at -$0.55. On average, analysts forecast that TVTX's EPS will be -$0.13 for 2026, with the lowest EPS forecast at -$7.84, and the highest EPS forecast at $2.84. In 2027, TVTX's EPS is forecast to hit $2.18 (min: $0.74, max: $6.29).

What is TVTX's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: TVTX) forecast ROE is 499.95%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.